| Idecabtagene vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium DK Hansen, S Sidana, LC Peres, C Colin Leitzinger, L Shune, ... Journal of Clinical Oncology 41 (11), 2087-2097, 2023 | 121 | 2023 |
| Evaluating daratumumab in the treatment of multiple myeloma: safety, efficacy and place in therapy D Dima, J Dower, RL Comenzo, C Varga Cancer management and research, 7891-7903, 2020 | 42 | 2020 |
| Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood cancer journal 13 (1), 117, 2023 | 31 | 2023 |
| Multiple myeloma therapy: emerging trends and challenges D Dima, D Jiang, DJ Singh, M Hasipek, HS Shah, F Ullah, J Khouri, ... Cancers 14 (17), 4082, 2022 | 30 | 2022 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 16 | 2023 |
| Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M C Gurnari, N Gagelmann, A Badbaran, H Awada, D Dima, S Pagliuca, ... Leukemia 37 (3), 717-719, 2023 | 14 | 2023 |
| Idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory multiple myeloma (RRMM) who have received a prior BCMA … CJ Ferreri, MAT Hildebrandt, H Hashmi, LO Shune, JP McGuirk, ... Blood 140 (Supplement 1), 1856-1858, 2022 | 13 | 2022 |
| Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients D Mao, H Hachem, H Chang, D Dima, J Dower, M Wismer, JK Erban, ... Breast Cancer Research and Treatment 184, 665-674, 2020 | 12 | 2020 |
| Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy LC Peres, LB Oswald, C Dillard, G De Avila, T Nishihori, BJ Blue, ... Blood 140 (Supplement 1), 623-625, 2022 | 11 | 2022 |
| Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience D Dima, JA Davis, N Ahmed, X Jia, A Sannareddy, H Shaikh, L Shune, ... Transplantation and cellular therapy 30 (3), 308. e1-308. e13, 2024 | 10 | 2024 |
| Impact of frailty on outcomes after chimeric antigen receptor T cell therapy for patients with relapsed/refractory multiple myeloma JA Davis, D Dima, N Ahmed, S DeJarnette, J McGuirk, X Jia, S Raza, ... Transplantation and Cellular Therapy 30 (3), 298-305, 2024 | 10 | 2024 |
| Toxicity profile of chimeric antigen receptor T-cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management M Markouli, F Ullah, S Unlu, N Omar, N Lopetegui-Lia, M Duco, F Anwer, ... Current Oncology 30 (7), 6330-6352, 2023 | 9 | 2023 |
| Early-Onset Colorectal Cancer: Current Insights F Ullah, AB Pillai, N Omar, D Dima, S Harichand Cancers 15 (12), 3202, 2023 | 9 | 2023 |
| Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation D Dima, S Mazzoni, F Anwer, J Khouri, C Samaras, J Valent, L Williams JCO Oncology Practice 19 (5), 265-275, 2023 | 9 | 2023 |
| Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice D Dima, F Ullah, S Mazzoni, L Williams, B Faiman, A Kurkowski, ... Cancers 15 (7), 2160, 2023 | 9 | 2023 |
| Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment S Sidana, LC Peres, H Hashmi, H Hosoya, C Ferreri, J Khouri, D Dima, ... Haematologica 109 (3), 777, 2024 | 8 | 2024 |
| Advances in the treatment of Hodgkin lymphoma: Current and future approaches F Ullah, D Dima, N Omar, O Ogbue, S Ahmed Frontiers in Oncology 13, 1067289, 2023 | 8 | 2023 |
| Precision oncology targets in biliary tract cancer N Farha, D Dima, F Ullah, S Kamath Cancers 15 (7), 2105, 2023 | 7 | 2023 |
| Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: US Myeloma Immunotherapy … H Hashmi, DK Hansen, LC Peres, OC Puglianini, C Freeman, G De Avila, ... Haematologica 109 (5), 1514, 2024 | 6 | 2024 |
| Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study D Dima, A Sannareddy, N Ahmed, JA Davis, H Shaikh, Z Mahmoudjafari, ... Blood 142, 3330, 2023 | 6 | 2023 |
